Bio-Rad Laboratories Class A
BIO
467 hedge funds and large institutions have $6.73B invested in Bio-Rad Laboratories Class A in 2023 Q3 according to their latest regulatory filings, with 59 funds opening new positions, 146 increasing their positions, 181 reducing their positions, and 58 closing their positions.
1.52% more ownership
Funds ownership: 76.74% → 78.26% (+1.5%)
2% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 58
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
0% less funds holding
Funds holding: 468 → 467 (-1)
7% less call options, than puts
Call options by funds: $24.6M | Put options by funds: $26.4M
6% less capital invested
Capital invested by funds: $7.19B → $6.73B (-$462M)
19% less repeat investments, than reductions
Existing positions increased: 146 | Existing positions reduced: 181
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$125M |
| 2 |
Parnassus Investments
San Francisco,
California
|
+$85.2M |
| 3 |
DM
Deerfield Management
New York
|
+$67.1M |
| 4 |
Millennium Management
New York
|
+$46.3M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$40.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
-$97.3M |
| 2 |
EC
Eminence Capital
New York
|
-$85.6M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$57.9M |
| 4 |
BlackRock
New York
|
-$54.4M |
| 5 |
AAM
Ardevora Asset Management
London,
United Kingdom
|
-$35M |
BIO Hedge Fund Activity: Q3 2023 in Review
467 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q3 2023, worth a combined $6.73B — down 6.4% from $7.19B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new BIO positions and 58 closed out — a net gain of 1 holder — while 146 added to existing stakes and 181 trimmed.
The largest buyer was Massachusetts Financial Services, opening a new position worth an estimated $125M. The largest seller was Champlain Investment Partners, exiting entirely with an estimated $97.3M sold.
- 467 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q3 2023, down from 468 in Q2 2023.
- Funds reported $6.73B of Bio-Rad Laboratories Class A stock for Q3 2023, down 6.4% quarter-over-quarter.
- 59 funds opened new Bio-Rad Laboratories Class A positions in Q3 2023 and 58 closed out, a net change of +1 holder.
- The largest Bio-Rad Laboratories Class A buyer in Q3 2023 was Massachusetts Financial Services, an estimated $125M added.
- The largest Bio-Rad Laboratories Class A seller in Q3 2023 was Champlain Investment Partners, an estimated $97.3M sold.
Based on aggregated 13F filings for Q3 2023.